Compare Hafnia Limited Common Shares (HAFN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hafnia Limited Common Shares vs Novartis AG — how do they compare? Hafnia Limited Common Shares trades at $10.24 (market cap $5.67B), while Novartis AG trades at $150.91 (market cap $279.90B). The key difference: Novartis AG is far larger — about 49.4× Hafnia Limited Common Shares's market cap, and Hafnia Limited Common Shares pays the higher dividend (10.44%). Which is the better fit depends on your goals — on Pluang, investors hold Hafnia Limited Common Shares for 0 Days and Novartis AG for 82 Days on average.
| HAFN | NVS | |
|---|---|---|
Market Cap | $5.67B | $279.90B |
Volume | 3,240,007 | 1,647,300 |
Sector | Industrials | Health |
52-Week High | $10.92 | $168.62 |
52-Week Low | $5.21 | $121.80 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $6.29B | $321.22B |
Dividend Yield | 10.44% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
Novartis (NVS) trades at $142.41, down 0.99% on the day, with a bearish technical signal and mixed earnings history. The company maintains strong profitability with a net income margin of 22.5% and ROE of 30.55%, though recent clinical trial setbacks and a $7.8 billion licensing deal with China's Abogen highlight strategic shifts. Cash flow from operations remains robust at $19.14 billion for 2025, supporting ongoing investments.
The outlook is cautious; analyst consensus is a 'Hold' with a $146 price target, reflecting concerns over pipeline execution despite solid fundamentals. Key risks include drug trial failures and regulatory scrutiny, while the current valuation at a P/E of 22.19 offers moderate appeal amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
